These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 37719014)

  • 41. Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for
    Thang SP; Violet J; Sandhu S; Iravani A; Akhurst T; Kong G; Ravi Kumar A; Murphy DG; Williams SG; Hicks RJ; Hofman MS
    Eur Urol Oncol; 2019 Nov; 2(6):670-676. PubMed ID: 31412006
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Banerjee SR; Kumar V; Lisok A; Chen J; Minn I; Brummet M; Boinapally S; Cole M; Ngen E; Wharram B; Brayton C; Hobbs RF; Pomper MG
    Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2545-2557. PubMed ID: 31399803
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Single-Arm, Low-Dose, Prospective Study of
    Wang G; Zang J; Jiang Y; Liu Q; Sui H; Wang R; Fan X; Zhang J; Zhu Z; Chen X
    J Nucl Med; 2023 Apr; 64(4):611-617. PubMed ID: 36328486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Early Prostate-Specific Antigen Changes and Clinical Outcome After
    Gafita A; Heck MM; Rauscher I; Tauber R; Cala L; Franz C; D'Alessandria C; Retz M; Weber WA; Eiber M
    J Nucl Med; 2020 Oct; 61(10):1476-1483. PubMed ID: 32111687
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
    Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
    BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Costs of radium-223 and the pharmacy preparation
    Quist SW; Paulissen JHJ; Wyndaele DNJ; Nagarajah J; Freriks RD
    J Med Econ; 2023; 26(1):366-375. PubMed ID: 36905581
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer.
    Touijer KA; Michaud L; Alvarez HAV; Gopalan A; Kossatz S; Gonen M; Beattie B; Sandler I; Lyaschenko S; Eastham JA; Scardino PT; Hricak H; Weber WA
    Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate Cancer.
    Weber M; Hadaschik B; Ferdinandus J; Rahbar K; Bögemann M; Herrmann K; Fendler WP; Kesch C
    Eur Urol Focus; 2021 Mar; 7(2):279-287. PubMed ID: 33483289
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical Trials of Prostate-Specific Membrane Antigen Radiopharmaceutical Therapy.
    Jadvar H; Colletti PM
    J Nucl Med Technol; 2023 Mar; 51(1):16-21. PubMed ID: 36599704
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GRPr Theranostics: Current Status of Imaging and Therapy using GRPr Targeting Radiopharmaceuticals.
    Kurth J; Potratz M; Heuschkel M; Krause BJ; Schwarzenböck SM
    Nuklearmedizin; 2022 Jun; 61(3):247-261. PubMed ID: 35668669
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Prognostic Value of Posttreatment
    Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L
    J Nucl Med; 2023 Jan; 64(1):69-74. PubMed ID: 35738906
    [No Abstract]   [Full Text] [Related]  

  • 52. 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology.
    Dalm SU; Bakker IL; de Blois E; Doeswijk GN; Konijnenberg MW; Orlandi F; Barbato D; Tedesco M; Maina T; Nock BA; de Jong M
    J Nucl Med; 2017 Feb; 58(2):293-299. PubMed ID: 27609789
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A prospective comparative study of [
    Gao X; Tang Y; Chen M; Li J; Yin H; Gan Y; Zu X; Cai Y; Hu S
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2177-2187. PubMed ID: 36811661
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical Characterisation of PSMA/GRPR-Targeting Heterodimer [
    Lundmark F; Abouzayed A; Rinne SS; Timofeev V; Sipkina N; Naan M; Kirichenko A; Vasyutina M; Ryzhkova D; Tolmachev V; Rosenström U; Orlova A
    Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672390
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
    Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer.
    Kabasakal L; AbuQbeitah M; Aygün A; Yeyin N; Ocak M; Demirci E; Toklu T
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1976-83. PubMed ID: 26227531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic Multidose Preparation of a Ready-to-Use
    Chakraborty A; Mitra A; Tawate M; Sahoo S; Lad S; Rakshit S; Gaikwad S; Basu S; Shimpi H; Banerjee S
    Cancer Biother Radiopharm; 2021 Oct; 36(8):682-692. PubMed ID: 34402687
    [No Abstract]   [Full Text] [Related]  

  • 58.
    Satapathy S; Mittal BR; Sood A; Das CK; Mavuduru RS; Goyal S; Shukla J; Singh SK
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1754-1764. PubMed ID: 34842950
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gastrin-releasing peptide receptor (GRPR) as a novel biomarker and therapeutic target in prostate cancer.
    Zhang H; Qi L; Cai Y; Gao X
    Ann Med; 2024 Dec; 56(1):2320301. PubMed ID: 38442298
    [No Abstract]   [Full Text] [Related]  

  • 60. Stability Evaluation and Stabilization of a Gastrin-Releasing Peptide Receptor (GRPR) Targeting Imaging Pharmaceutical.
    Ghosh A; Woolum K; Kothandaraman S; Tweedle MF; Kumar K
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31398865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.